**Title:** Broad Spectrum Influenza Antiviral

**Invention:** This technology is four candidate small molecules used to treat influenza infections. These molecules target a highly conserved mechanism of influenza viruses and therefore have the ability to offer broad spectrum protection for both influenza A, influenza B and many influenza A subtypes. Preliminary studies show these small molecules have a higher barrier of resistance by multiple influenza virus types.

**Background:** Even with vaccinations against the influenza virus, the flu affects millions of people worldwide and results in nearly half a million deaths annually. To help treat individuals who have contracted the influenza virus, the CDC recommends three antiviral drugs, each of which must be taken within 48 hours after the onset of flu symptoms in order to be effective. Furthermore, many influenza virus strains are now becoming increasingly resistant to the current drugs on the market. Therefore there is a large need for the development of new drugs with a higher barrier to resistance.

**Applications:**

- Treatment of influenza A, influenza B and many influenza A subtypes

**Advantages:**

- New antiviral target
- Broad-spectrum influenza antiviral activity
- Provides higher barrier to drug resistance

**Licensing Manager:**

Kaitlyn Norman-Powers

KaitlynN@tla.arizona.edu
Inventors

Jun Wang

Assistant Professor, Pharmacology and Toxicology